Skip to Content

A Mab A Case Study In Bioprocess Development __exclusive__ Today

Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%.

to find the "Design Space"—the range where these factors can vary without affecting the product. PharmTech.com 3. Downstream Process Development (Purification) A Mab A Case Study In Bioprocess Development

Templates

A Mab A Case Study In Bioprocess Development __exclusive__ Today

A Mab A Case Study In Bioprocess Development __exclusive__ Today

Stop spending hours designing and formatting your Excel templates. Download our ready-to-use reporting templates for Excel today.

A Mab A Case Study In Bioprocess Development

Grow Smarter With the Vena Community

Join for free today to connect with the brightest minds in finance and get access to Excel templates, CPE/CPD courses, exclusive content and more.

Learn More
A Mab A Case Study In Bioprocess Development

Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%.

to find the "Design Space"—the range where these factors can vary without affecting the product. PharmTech.com 3. Downstream Process Development (Purification)